MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (mnc pharma)
- GSK PHARMA
GSK PHARMA Share Price 
(GLXO)
Here is the latest stock price and chart of GSK Pharma. For more details, see the GSK Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Apr 18, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)1,298.10 | Open (Rs) 1,308.00 | High (Rs) 1,308.00 | Low (Rs) 1,290.00 |
| % Change-0.15 | Volume 1,214 | Value (Rs) 1,572,127 | 52-Week H/L 1,812.00 / 1,135.88 |
| Live NSE Quotes | Apr 18, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)1,299.90 | Open (Rs) 1,293.00 | High (Rs) 1,300.15 | Low (Rs) 1,292.40 |
| % Change0.02 | Volume 10,622 | Value (Rs) 13,787,574 | 52-Week H/L 1,800.05 / 1,153.98 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 24.08 | P/E Ratio (x) 53.91 | Market Cap (Rs m) 219,905.93 | P/BV (x) 10.69 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
GSK PHARMA Share Price Today:
GSK PHARMA last traded price was down 0.2% to Rs 1,298.1 on the BSE. On the NSE, GSK PHARMA last traded price was up 0.0% to Rs 1,299.9. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.3%. And the benchmark S&P BSE SENSEX was at 39,140.3 (down 0.3%).
Over the last 30 days, the GSK PHARMA share price is up 0.6%. And over the last one year, GSK PHARMA share price is up 10.0%.
|
| |
Today's Market
Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)
Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.
Related Views On News
GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)
Feb 5, 2019 | Updated on Feb 5, 2019For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)
Oct 23, 2018 | Updated on Oct 23, 2018For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)
Apr 9, 2019It's a matter of time before the stocks catch the fancy of the markets and big investors.
3 Indian Stocks with Amazon-Like Potential(Profit Hunter)
Apr 10, 2019We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.
A 90% Chance of Auto Stocks Moving Up This April(Profit Hunter)
Apr 5, 2019The Auto index ended on a positive note in the month of April in 9 out of last 10 years. This Auto stock is best placed to benefit from the upswing in this sector.
This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)
Apr 10, 2019How Dell got its mojo back.
This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)
Apr 12, 2019This critical business strategy has enabled companies to scale their operations faster.
MoreTRACK GSK PHARMA
- Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK PHARMA
GSK PHARMA 8-QTR ANALYSIS
COMPARE GSK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.